Psomagen Inc.

Psomagen Inc., a subsidiary of South Korea-based Macrogen, Inc., delivers genomic sequencing, proteomics analysis, and multi-omics data services to federal civilian health and agricultural agencies as a prime contractor, competing predominantly under full-and-open procurement without set-aside designations. The for-profit Rockville, Maryland-based manufacturer operates CLIA-certified and CAP-accredited laboratory facilities and holds no SBA certifications; recent awards show occasional small-business set-asides but the vendor is not designated as a small business across its prime footprint.

Psomagen's customer concentration is extreme: the National Heart, Lung and Blood Institute anchors 45 percent of recent awards by count and 95 percent of combined potential value ($501.5 million of $526.7 million total), driven almost entirely by a single $500 million indefinite delivery contract awarded in September 2023 to establish and operate the Centralized Omics Resource for the Trans-Omics for Precision Medicine (TOPMed) initiative through September 2033. The National Institute on Aging ranks second with 22 awards valued at $15.3 million; the National Institute of Allergy and Infectious Diseases and related NIH acquisitions account for approximately 11 percent of awards; and the Department of Agriculture contributes a secondary stream of sequencing work. The top five customers by potential value—NHLBI, NIA, the National Institute on Drug Abuse, NIAID, and the National Institute of Child Health and Human Development—account for 99 percent of combined value. Two parent IDIQs carry task-order activity: a $80,000 USDA Plant Protection and Quarantine Indefinite Delivery Contract for Sanger sequencing services to identify intercepted pests (3 task orders, $41 thousand), and a separate NIAID vehicle with 1 task order valued at $73 thousand.

Recent representative work includes a $7.5 million National Institute on Aging purchase order (August 2024) for whole genome sequencing services on 500 samples supporting neurodegenerative disease research, a $532.5 thousand NIA award (January 2025) for long-read sequencing of 500 human DNA samples at 25X coverage for the Global Parkinson's Genetics Program, a $313.5 thousand NIA single-cell multiome sequencing purchase order (February 2024), a $3.85 million NIA neurodegenerative disease whole-genome-sequencing award (July 2023), multiple NHLBI sickle-cell-disease proteomics contracts using the Olink Explore HT platform (19 purchase orders ranging from $14,100 to $229,104 across June 2025–May 2026), USDA Plant Protection and Quarantine delivery orders for pest-identification Sanger sequencing, and FDA whole-genome-sequencing work for edited pig-genome validation. Work spans whole-genome sequencing, RNA sequencing (bulk and single-cell), epigenome profiling, proteomics analysis, and advanced bioinformatics—nearly all delivered as firm-fixed-price purchase orders and delivery orders rather than cost-reimbursable arrangements.

Activity has grown modestly from 17 awards in 2022 to a peak of 21 in 2024, though recent volume (4 awards in 2026 year-to-date and 16 in 2025) suggests a flattening trajectory. Six awards (combined potential value $312 thousand) reach completion within the next twenty-four months and face recompete exposure. The SCI dataset, which covers federal service contracts above the $150,000 reporting threshold, captured $3.6 million in invoiced revenue across eight prime records spanning FY2022–FY2024, with FY2024 showing $2.5 million across 0.6 FTEs. This SCI figure represents only a small subset of Psomagen's total federal revenue and excludes goods, products, micro-purchases, and classified work. Across SCI-reportable prime contracts, Psomagen delivered all work with internal staff (zero percent sub-hours share), and government-paid hourly rates ranged from a 10th percentile of $625.69/hr through a median of $1,303.20/hr to a 90th percentile of $1,824.53/hr, reflecting a mix of specialized technical labor and project management. Psomagen operates 100 percent as a prime contractor with no subcontract activity in the source data, positioning it as a direct service delivery provider rather than a sub-tier player.

The vendor's federal footprint centers on high-complexity genomics and molecular biology services for NIH-led precision medicine and disease-research initiatives. The $500 million TOPMed IDV underpins the vendor's federal presence and creates significant recompete risk concentrated in a single customer and vehicle through 2033. Outside that anchor, Psomagen has cultivated a diversified but lower-dollar stream across NIA, NIAID, USDA, FDA, and related health agencies, with work characterized by technical specialization in advanced sequencing platforms and omics analysis rather than broad IT or professional-services competition.